Effectiveness of N- Acetylcysteine with Dexamethasone (name of a drug) in liver cancer.
Not Applicable
- Conditions
- Health Condition 1: K77- Liver disorders in diseases classified elsewhere
- Registration Number
- CTRI/2023/08/056845
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.All patients undergoing TACE procedure
2.Valid Consent
3.Age 18-65 years
Exclusion Criteria
1.Child Pugh C, Child Pugh B > 8
2.HCC patients with a curative therapy (Ablation, Resection or LT)
3.ECOG Performance Status 3-4
4.Pregnancy
5.History of allergic reaction from NAC
6.significant cardiopulmonary disease
7.UGI bleed within last 28 days
8.Recent surgery within last 28 days
9.Documented febrile illness in last 1 weeks
10.Uncontrolled Diabetes (FBS > 200, HBA1C > 8)
11.Uncontrolled Hypertension (BP > 160/100)
12.Structural kidney disease with eGFR < 60 ml/min.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevention of post embolisation syndrome at 72 hours with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 72 hour
- Secondary Outcome Measures
Name Time Method Decrease in the duration of hospitalisation with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 2 weeks;Prevention of post TACE decompensation at 2 weeks with addition of Dexamethasone to NAC in patients undergoing transarterial chemoembolisation for HCCTimepoint: 2 weeks;The safety of Dexamethasone & NAC in patients undergoing transarterial chemoembolisation for HCC.Timepoint: 2 weeks